Metabolic endoscopy: Today's science-tomorrow's treatment.
United European Gastroenterol J
; 8(6): 685-694, 2020 07.
Article
em En
| MEDLINE
| ID: mdl-32628898
ABSTRACT
Obesity, type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis are increasing pandemic metabolic disorders. Lifestyle intervention (LSI) is the cornerstone treatment for these but is successful as standard care alone in only a few patients, given the modest weight loss at mid and long term. Conversely, bariatric surgery is the only proven effective treatment for these metabolic disorders, albeit offered only in a small percentage of cases because of its invasiveness and cost. The so-called endoscopic bariatric and metabolic therapies (EBMTs) include new, less-invasive technologies such as intragastric balloons, aspiration therapy, endoscopic sleeve gastroplasty, diversion devices, and duodenal mucosal resurfacing, currently at various stages of development. EBMTs, as an add-on to LSI, might represent an effective treatment filling the gap between medical and surgical management, taking into account, however, that obesity and its associated comorbidities constitute a chronic disease that needs lifelong therapy. In this review we describe the current scientific evidence surrounding EBMTs as well as future opportunities for such treatments in managing obesity and metabolic disorders.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Endoscopia do Sistema Digestório
/
Diabetes Mellitus Tipo 2
/
Cirurgia Bariátrica
/
Hepatopatia Gordurosa não Alcoólica
/
Obesidade
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article